New T Cell Therapy Could Transform Glioblastoma Care
Recurrent glioblastoma leaves patients with almost no effective treatments to fall back on. Standard therapies typically combine surgery with chemotherapy, but the disease usually comes back in a harsher, harder-to-treat form. Median survival after recurrence is less than a year. A new Phase I trial published August 6 in the journal Nature Medicine suggests an experimental immunotherapy may finally offer these patients another option. The treatment relies on CAR-T cell therapy, an approach that re-engineers a patient's own immune cells to hunt down cancer. Researchers trained the modified cells, known as CAR-T cells, to target B7-H3, a protein found on the surface of most glioblastomas but largely absent from healthy tissue. Scientists…

